The company’s sales reached RON208.9 million, 17% higher than in the same period of 2021, and net assets increased 12.7% to RON374.9 million. Debt shrank from RON86 million to RON83.8 million.
At the end of September, the company announced that investment in the plant inaugurated in Bucharest in 2021 had reached more than EUR44 million, the largest greenfield investment in the pharmaceutical sector in Romania.
Biofarm shares have lost 28% since the beginning of the year, amid total transactions of RON7.3 million. Owned 51.6% by SIF Muntenia and 36.7% by SIF Banat-Crisana, the company has a capitalization of RON593.2 million, according to the Bucharest Stock Exchange.
(English version by Loredana Fratila-Cristescu)